目的 观察多西他赛三药及两药联合对胃癌根治术后辅助化学疗法（化疗）的疗效比较及不良反应。 方法 回顾性分析解放军总医院2006年1月－2011年12月42 例胃癌根治术后患者的临床资料，其中有22例、20例患者分别接受以多西他赛为基础的三药、两药联合辅助化疗。三药联合：多西他赛注射液+铂类+氟尿嘧啶/卡培他滨片/替吉奥；两药联合：多西他赛注射液+氟尿嘧啶/卡培他滨片/替加氟或多西他赛注射液+铂类；主要观察终点：无疾病生存期（DFS），次要观察终点：预后因素分析、复发转移情况、不良反应及亚组分析。 结果 两组中位DFS分别为9.530、7.170个月（P=0.646）；性别、年龄、肿瘤浸润深度、脉管癌栓、淋巴结清扫范围是患者早期复发转移的不良预后因素，三药联合组肝转移率高于两药联合组（P=0.008）；主要不良反应为恶心、呕吐、白细胞减少、腹泻、脱发、血小板减少等，多为1～2级，可耐受，三药联合组较两药联合组易出现不良反应（P=0.011），以恶心、呕吐为主。 结论 胃癌根治术后以多西他赛为基础的辅助化疗三药、两药联合对患者疗效及预后无明显差异，且两种辅助疗法不良反应基本可耐受。
目的 探讨新辅助化学疗法（化疗）对结直肠癌手术患者炎症因子水平的影响。 方法 回顾2008年1月－2009年12月诊断为结直肠癌的487例患者的临床资料，剔除不符合研究条件者后，共390例，以是否接受过新辅助化疗分为术前化疗组（化疗组）156例与对照组234例进行研究。分别比较两组在入院时、术前、术后的炎症因子水平。 结果 入院时两组外周血白细胞、C反应蛋白（CRP）、纤维蛋白原、血清淀粉样蛋白水平差异均无统计学意义（P＞0.05）；术后化疗组CRP水平[（64.09 ± 60.24）mg/L]低于对照组[（87.80 ± 61.54）mg/L]，差异有统计学意义（P＜0.05）；其余炎症因子组间差异无统计学意义（P＞0.05）。 结论 新辅助化疗不会刺激机体产生免疫反应，且有一定的安全性。
目的 评估对降低食管癌术后患者肺部并发症发生的预防措施。 方法 采用logistic回归的统计学方法，对胸外科1组2008年1月－2011年12月间行食管癌手术的109例患者进行回顾性分析，对所有可能的影响因素纳入研究。 结果 共计有24例患者发生肺部并发症（包括肺炎、急性呼吸窘迫综合征）；计算体质量指数测定值，累计有31例患者术前存在营养不良体质量指数测定值＜18 kg/m2，其中有11例发生肺部并发症。吸烟和糖尿病是发生肺部并发症的独立危险因素（P=0.017，0.048），34名患者进行了新辅助化学疗法（化疗），未明显增加术后肺部并发症的风险（P=0.080）。术中限制液体输入的患者，术后肺部并发症明显减少（P=0.008）。 结论 术前患者存在营养不良、吸烟史、糖尿病史及术中输入较多液体等都是患者发生肺部并发症的高危因素，但新辅助化疗未见引起肺部并发症升高。
Objective To assess the impact of adjuvant chemotherapy (ACH) on the survival of patients with pT3 urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC). Methods We retrospectively analyzed the clinical and follow-up data of 223 UCB patients who underwent RC between January 2005 and June 2015. None of the patients received neoadjuvant chemotherapy. Of all the patients, 75 (33.6%) were diagnosed as pT3 cancer (including 32 pT3a and 43 pT3b patients). The follow-up data were up to June 2015. Kaplan-Meier method with log-rank test was used to estimate and compare overall survival (OS) and cancer-specific survival (CSS) between groups. Multivariate Cox proportional hazard models were used to identify predictors of OS and CSS. Results The short-term total effective rate of gemcitabine and cisplatin assisted chemotherapy in the treatment of pT3 UCB was 60.0%. Five-year OS rate (47.9%vs. 43.3%) and CSS rate (57.4%vs. 57.6%) were similar in the pT3a and pT3b groups (P=0.682 and 0.796, respectively). In pT3 patients, adjuvant chemotherapy was an independent predictor for OS (P=0.032). On multivariate analysis, according to the pT3 sub-stage, ACH was significantly associated with improved OS [hazard ratio (HR) =0.37; 95% confidence interval (CI) (0.15, 0.68),P=0.006] and CSS [HR=0.34, 95%CI (0.12, 0.86),P=0.022] in the pT3b group only. Conclusion Because pT3b cancer is characterized by macroscopic peri-vesical tissue invasion, patients may obtain an OS benefit from the administration of adjuvant chemotherapy.
Objective To investigate the efficacy and safety of neo-adjuvant chemotherapy for stage ⅠB2-ⅡB cervical cancer. Methods From June 2012 to December 2014, 66 patients with stage ⅠB2-ⅡB cervical cancer were selected and treated by PT (cisplatin/ carboplatin and taxol/docetaxel) as neo-adjuvant chemotherapy prior to surgery. Neo-adjuvant chemotherapy response and toxicity were collected and analyzed. Results The extinctive condition of tumor by neo-adjuvant chemotherapy: the complete remission rate was 10.6% (7/66), partial remission rate was 59.1% (39/66), and the total effective rate was 69.7%. The main toxicities were myelosuppression (59.1%, 39/66) and gastrointestinal reactions (33.3%, 22/66). The toxicities could be tolerated or relieved by prevention and treatment. The effective rate of chemotherapy for cervical squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma was 72.6%, 33.3% and 0%, respectively, with significant differences among the three types (P<0.05). The effective rate of chemotherapy for high, medium and low differentiated cervical cancer was 100.0%, 77.3% and 55.9%, respectively, with significant differences among the three degrees (P<0.05). Conclusions Neo-adjuvant chemotherapy is proved to be a safe and effective complementary treatment for most patients with locally advanced cervical cancer. Due to the limitation of sample size, the correlations between therapeutic effect and tumor differentiation degree and between therapeutic effect and pathological type need further study.